CStone Pharmaceuticals (HKG:2616) submitted the Phase I-B trial application in Australia for its large B-cell lymphoma (DLBCL) drug, according to a Thursday filing with the Hong Kong bourse.
CS5001 is an ROR1-targeting antibody-drug conjugate (ADC) that works with first-line standard-of-care (SoC) to diffuse large B-cell lymphoma (DLBCL), the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。